Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CD25/Treg-depleted donor lymphocytes

A preparation of allogeneic peripheral blood mononuclear cells (PBMCs) derived from an 8/8 HLA-matched donor that have been selectively depleted of CD4+CD25hiFoxp3+ regulatory T cells (Tregs; CD25hi Tregs) with potential to enhance graft-versus-tumor (GVT) immune responses in patients with myeloid relapse following a hematopoietic stem cell transplant (HSCT) from a matched donor. Following collection and ex-vivo depletion of CD25hi Tregs from PBMCs derived from the original donor, the CD25/Treg-depleted donor lymphocytes are infused into the patient. Upon administration, the CD25/Treg-depleted donor lymphocyte infusion (DLI) may enhance the proliferation of CD4+ and CD8+ effector T cells (Teffs) and potentially induce curative GVT immune responses in patients with myeloid relapse following HSCT.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic Treg-depleted donor lymphocytes
CD25/Treg-depleted donor lymphocytes
CD25hi-depleted donor lymphocytes
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search